Analytical identity of BPC-157: a 15-mer with a simple mass

Analytical identity of BPC-157: a 15-mer with a simple mass Writing it up because I had to work it out twice and would rather nobody else did.

Something about analytical identity of BPC-157 does not reconcile and I would like a second pair of eyes before I decide which half is wrong.

Two sources, both reputable, giving figures that cannot both be right unless they are measuring different quantities. My suspicion is that they are, and I cannot see how.

Taking the opening post at face value and following it one step further.

Acetate content can be a substantial fraction of the mass in a short peptide. A vial labelled 5 mg may contain appreciably less than 5 mg of peptide, and the certificate frequently does not say.

On identity: a short sequence gives a distinctive mass and a distinctive fragmentation pattern, so mass spectrometry is genuinely informative here. It is also the analysis least often supplied.

That holds for the case as described. Change the assumptions and it may not.

Short peptides like these are chromatographically simple, so a purity result is comparatively easy to obtain and comparatively easy to make look good on a lazy gradient. Ask for the method.

I would be interested in a counterexample if anyone has one.

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

That holds under the stated conditions and I have stated them.

This follows post #5 rather than contradicting it.

Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.

The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.

The honest answer is that it depends, and here is what it depends on.

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

Take the reasoning and check the arithmetic; I do not always get it right.